‘Unanswered questions’ surround systemic sclerosis lung disease
HUNTINGTON BEACH, Calif. — Treatment options are coming into focus for patients with interstitial lung disease in systemic sclerosis, albeit slowly, according to a presenter at the Congress of Clinical Rheumatology West.
“Make sure everyone with systemic sclerosis is getting screened for interstitial lung disease,” Laura Hummers, MD, ScM, clinical director of the division of rheumatology at Johns Hopkins University, and director of the Johns Hopkins Scleroderma Center, told Healio. “ILD is very common in scleroderma patients.”
All patients with newly diagnosed SSc